Skip to content
Disclosery

venBio Partners LLC

Follow

13F filer, CIK 1776382, SAN FRANCISCO, CA

venBio Partners LLC reported $114,756,634 across 6 holdings for the quarter ended 2025-06-30, in a 13F-HR filed 2025-08-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000905148-25-002929

Period
2025-06-30
Reported value
$115M
Holdings
6
Top 10 weight
100%
New
1
Sold out
2

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ALMSadded+1,832,405$5.5M
LYELnew+473,479$4.19M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ACELYRIN INCexited-3,806,410-$9.4M
LYELL IMMUNOPHARMA INCexited-7,102,190-$3.82M
ARTVreduced-50,000-$75.5K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q2 2025

Share positions as resolved from 13F-HR 0000905148-25-002929, largest first. % of portfolio is the value over $114,756,634, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 4,289,304 shares; 2024Q4: 4,289,304 shares; 2025Q1: 4,289,304 shares; 2025Q2: 4,289,304 shares 4,289,304$75.5M65.78%0Timeline
HRMYHARMONY BIOSCIENCES HLDGS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 614,594 shares; 2024Q4: 539,194 shares; 2025Q1: 489,194 shares; 2025Q2: 489,194 shares 489,194$15.5M13.47%0Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,826,048 shares; 2024Q4: 2,787,398 shares; 2025Q1: 2,787,398 shares; 2025Q2: 4,619,803 shares 4,619,803$13.9M12.08%+1,832,405Timeline
LYELLYELL IMMUNOPHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 473,479 shares 473,479$4.19M3.65%newTimeline
ALXOALX ONCOLOGY HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 9,699,925 shares; 2024Q4: 9,699,925 shares; 2025Q1: 9,699,925 shares; 2025Q2: 9,699,925 shares 9,699,925$4.03M3.51%0Timeline
ARTVARTIVA BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2023Q3: restricted; 2023Q4: restricted; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,519,971 shares; 2024Q4: 1,519,971 shares; 2025Q1: 1,198,975 shares; 2025Q2: 1,148,975 shares 1,148,975$1.73M1.51%-50,000Timeline

Sold out in Q2 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ACELYRIN INCACELYRIN INC3,806,410$9.4Mshares
LYELL IMMUNOPHARMA INCLYELL IMMUNOPHARMA INC7,102,190$3.82Mshares

How Q2 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000905148-25-002929 base2025-08-14acceptance time not in the bulk data set